The most critical step in diagnosing a sleep disorder is often the most tedious. A sleep technologist must manually review hours of overnight physiological data, marking every breath, brain wave, and muscle twitch to produce a report. It is a bottleneck that leaves an estimated 80% of sleep apnea patients undiagnosed [EnsoData, retrieved 2026]. For nearly a decade, EnsoData has been building an FDA-cleared AI to clear that logjam, not by replacing clinicians, but by giving them back the one resource they cannot scale: time.
Founded in 2015 by three University of Wisconsin-Madison students, the company’s flagship product, EnsoSleep, automates the scoring of polysomnography (PSG) and home sleep apnea tests (HSAT). The cloud-based platform, which received FDA clearance in 2017, uses machine learning to analyze waveforms from EEG, EOG, and respiratory signals [Sleep Review, retrieved 2026]. The clinical claim is straightforward: less manual labor per test means more patients can be screened. Customer testimonials and company data suggest the efficiency gains are substantial, reporting average time savings of 62% on PSGs and 68% on HSATs [EnsoData, retrieved 2026]. For a home test, that can mean reducing a 30-minute scoring task to about six minutes.
The clinical workflow wedge
EnsoData’s wedge is not a consumer app or a direct diagnostic. It is a tool built for the sleep lab’s existing workflow. The software integrates with a clinic’s existing hardware, ingesting raw waveform data and returning a scored study for a technologist’s final review and sign-off. This positioning is deliberate. By automating the repetitive scoring task while keeping the expert in the loop, the company aims to standardize analysis and reduce inter-scorer variability, a known challenge in sleep medicine.
The traction metric that matters here is clinic adoption, not just algorithmic accuracy. The company reports its software is now used in more than 400 sleep clinics across the United States, including health systems like CommonSpirit Health and Northwell Health [Sleep Review, retrieved 2026]. This installed base provides a continuous feedback loop, generating the annotated waveform data that further refines EnsoSleep’s models. The recent $20 million Series B round, led by Questa Capital, brings EnsoData’s total disclosed funding to just over $50 million and is explicitly aimed at expanding this commercial footprint [MedCity News, June 2025] [EnsoData, June 2025].
Leadership and strategic backing
The company’s leadership has evolved from its founding trio to include seasoned medtech operators. Justin Mortara, who joined as CEO in November 2022, now steers the company, while co-founders Chris Fernandez, Sam Rusk, and Nick Glattard remain deeply involved as Chief Research Officer, President, and Chief Technology Officer, respectively [EnsoData, retrieved 2026]. The 2021 Forbes 30 Under 30 recognition for all three founders underscored their early impact [Sleep Review, retrieved 2026].
A significant vote of confidence came in 2022 with a $10 million strategic minority investment from Inspire Medical Systems, a publicly-traded maker of an implantable device for moderate to severe sleep apnea [Inspire Medical Systems, Jan 2022]. This is more than capital; it signals a potential pathway into a connected treatment ecosystem. Automating and expanding diagnostics creates a larger funnel of identified patients, a portion of whom may be candidates for advanced therapies like Inspire’s.
Strategic Investment (2022) | 10 | M USD
Series B (2025) | 20 | M USD
Navigating a crowded diagnostic field
The market for sleep diagnostics and management software is fragmented, with numerous players from legacy medical device companies to pure-play software startups. EnsoData’s competitive set includes platforms like Somnoware (now owned by ResMed), Cerebra, and a host of specialized scoring tools. Its most credible moats are its first-mover FDA clearance and its focused dataset of scored sleep studies.
- Regulatory head start. EnsoSleep’s 2017 FDA clearance remains a tangible barrier. Competitors must undergo the same rigorous review process to make equivalent automated scoring claims for clinical use.
- Proprietary data flywheel. Each clinic using EnsoSleep contributes to a growing repository of clinician-validated waveform analyses. This dataset, unique in its scale and clinical annotation, is difficult for a new entrant to replicate quickly.
- Integration posture. By selling into the existing clinical workflow rather than trying to displace it, EnsoData avoids the steep change management hurdles that plague more disruptive digital health tools.
The primary competitive pressure is less about a head-to-head feature war and more about the pace of market education and sales execution. The company must continue converting traditional sleep labs, which may be hesitant to change long-established manual processes, while also fending off larger medical technology firms that could decide to build or buy similar capabilities.
The next twelve months
The fresh Series B capital is earmarked for commercial team growth and platform development [Milwaukee Business Journal, June 2025]. The near-term milestones to watch will be deeper integrations with major electronic health record systems and the launch of new AI modules for analyzing other cardiorespiratory conditions. A key hire in 2024, Chief Medical Officer Dr. Nathaniel Watson,a past president of the American Academy of Sleep Medicine,signals a commitment to clinical rigor as the product scope expands [EnsoData, retrieved 2026].
The ultimate patient population here is the hundreds of millions globally with obstructive sleep apnea, a condition linked to hypertension, heart disease, and stroke. For them, the standard of care today often involves a long wait for a sleep study, followed by a weeks-long delay for manual scoring and interpretation, before a diagnosis is even confirmed. It is a process that can feel as slow as a heartbeat during apnea. EnsoData’s bet is that by accelerating the clinician’s work, they can shorten that diagnostic odyssey, turning a bottleneck into a pathway for the 54 million Americans, and millions more worldwide, who are waiting to breathe easier.
Sources
- [EnsoData, retrieved 2026] Company Website | https://www.ensodata.com/
- [Sleep Review, retrieved 2026] EnsoData Company Profile | https://sleepreviewmag.com/sleep-treatments/diagnostics/software/ensodata/
- [MedCity News, June 2025] EnsoData Raises $20M Series B | https://medcitynews.com/2025/06/ensodata-series-b-funding-sleep-apnea-ai/
- [EnsoData, June 2025] Series B Press Release | https://www.ensodata.com/press_article/
- [Inspire Medical Systems, Jan 2022] Strategic Investment Announcement | https://investors.inspiresleep.com/news-releases/news-release-details/inspire-medical-systems-makes-strategic-minority-investment
- [Milwaukee Business Journal, June 2025] AI health startup EnsoData lands $20M | https://www.bizjournals.com/milwaukee/news/2025/06/25/ensodata-raises-20m-to-expand-commercial-team.html